Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Factive Should Be Used Second-Line For Treatment Of Acute Sinusitis – Cmte.

Executive Summary

Oscient's Factive would be a second-line treatment of acute bacterial sinusitis, FDA's Anti-Infective Drugs Advisory Committee said in recommending against approval of a supplemental claim for gemifloxacin in ABS Sept. 12.

You may also be interested in...



Antibiotic Efficacy Rereview Would Be Triggered Only By Safety Issues – FDA

Absent safety concerns, FDA is not planning to seek superiority trials for currently-marketed antibiotics, despite advisory committee concerns about the approval standards used for Sanofi-Aventis' Ketek (telithromycin)

Antibiotic Efficacy Rereview Would Be Triggered Only By Safety Issues – FDA

Absent safety concerns, FDA is not planning to seek superiority trials for currently-marketed antibiotics, despite advisory committee concerns about the approval standards used for Sanofi-Aventis' Ketek (telithromycin)

Past FDA Action Is Not Necessarily Predictive Of Future Behavior – Temple

Sponsors should not assume clinical trials are immune from evaluation according to updated efficacy standards, even if parameters are initially agreed upon with the agency

UsernamePublicRestriction

Register

ID007083

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel